These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
224 related articles for article (PubMed ID: 18383390)
1. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Kremer JM; Genant HK; Moreland LW; Russell AS; Emery P; Abud-Mendoza C; Szechiński J; Li T; Teng J; Becker JC; Westhovens R Arthritis Rheum; 2008 Apr; 58(4):953-63. PubMed ID: 18383390 [TBL] [Abstract][Full Text] [Related]
2. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression. Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491 [TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Genovese MC; Schiff M; Luggen M; Becker JC; Aranda R; Teng J; Li T; Schmidely N; Le Bars M; Dougados M Ann Rheum Dis; 2008 Apr; 67(4):547-54. PubMed ID: 17921185 [TBL] [Abstract][Full Text] [Related]
4. Longterm safety, efficacy, and inhibition of structural damage progression over 5 years of treatment with abatacept in patients with rheumatoid arthritis in the abatacept in inadequate responders to methotrexate trial. Kremer JM; Peterfy C; Russell AS; Emery P; Abud-Mendoza C; Sibilia J; Becker JC; Westhovens R; Genant HK J Rheumatol; 2014 Jun; 41(6):1077-87. PubMed ID: 24786925 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Schiff M; Keiserman M; Codding C; Songcharoen S; Berman A; Nayiager S; Saldate C; Li T; Aranda R; Becker JC; Lin C; Cornet PL; Dougados M Ann Rheum Dis; 2008 Aug; 67(8):1096-103. PubMed ID: 18055472 [TBL] [Abstract][Full Text] [Related]
6. Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes. Bathon J; Robles M; Ximenes AC; Nayiager S; Wollenhaupt J; Durez P; Gomez-Reino J; Grassi W; Haraoui B; Shergy W; Park SH; Genant H; Peterfy C; Becker JC; Covucci A; Moniz Reed D; Helfrick R; Westhovens R Ann Rheum Dis; 2011 Nov; 70(11):1949-56. PubMed ID: 21821865 [TBL] [Abstract][Full Text] [Related]
7. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Kremer JM; Russell AS; Emery P; Abud-Mendoza C; Szechinski J; Westhovens R; Li T; Zhou X; Becker JC; Aranda R; Peterfy C; Genant HK Ann Rheum Dis; 2011 Oct; 70(10):1826-30. PubMed ID: 21893583 [TBL] [Abstract][Full Text] [Related]
8. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Kremer JM; Genant HK; Moreland LW; Russell AS; Emery P; Abud-Mendoza C; Szechinski J; Li T; Ge Z; Becker JC; Westhovens R Ann Intern Med; 2006 Jun; 144(12):865-76. PubMed ID: 16785475 [TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Westhovens R; Robles M; Ximenes AC; Nayiager S; Wollenhaupt J; Durez P; Gomez-Reino J; Grassi W; Haraoui B; Shergy W; Park SH; Genant H; Peterfy C; Becker JC; Covucci A; Helfrick R; Bathon J Ann Rheum Dis; 2009 Dec; 68(12):1870-7. PubMed ID: 19124524 [TBL] [Abstract][Full Text] [Related]
10. Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting. Alten R; Burkhardt H; Feist E; Krüger K; Rech J; Rubbert-Roth A; Voll RE; Elbez Y; Rauch C Arthritis Res Ther; 2018 Jan; 20(1):1. PubMed ID: 29329602 [TBL] [Abstract][Full Text] [Related]
11. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. Guyot P; Taylor P; Christensen R; Pericleous L; Poncet C; Lebmeier M; Drost P; Bergman G Arthritis Res Ther; 2011; 13(6):R204. PubMed ID: 22151924 [TBL] [Abstract][Full Text] [Related]
12. Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy. Genovese MC; Schiff M; Luggen M; Le Bars M; Aranda R; Elegbe A; Dougados M J Rheumatol; 2012 Aug; 39(8):1546-54. PubMed ID: 22798265 [TBL] [Abstract][Full Text] [Related]
13. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. Emery P; Kosinski M; Li T; Martin M; Williams GR; Becker JC; Blaisdell B; Ware JE; Birbara C; Russell AS J Rheumatol; 2006 Apr; 33(4):681-9. PubMed ID: 16568505 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. Westhovens R; Kremer JM; Moreland LW; Emery P; Russell AS; Li T; Aranda R; Becker JC; Qi K; Dougados M J Rheumatol; 2009 Apr; 36(4):736-42. PubMed ID: 19273451 [TBL] [Abstract][Full Text] [Related]
15. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data. Yazici Y; Moniz Reed D; Klem C; Rosenblatt L; Wu G; Kremer JM Clin Exp Rheumatol; 2011; 29(3):494-9. PubMed ID: 21722499 [TBL] [Abstract][Full Text] [Related]
16. Decreased external home help use with improved clinical status in rheumatoid arthritis: an exploratory analysis of the Abatacept in Inadequate responders to Methotrexate (AIM) trial. Li T; Gignac M; Wells G; Shen S; Westhovens R Clin Ther; 2008 Apr; 30(4):734-48. PubMed ID: 18498922 [TBL] [Abstract][Full Text] [Related]
17. Long-term safety and efficacy of treatment with subcutaneous abatacept in Japanese patients with rheumatoid arthritis who are methotrexate inadequate responders. Amano K; Matsubara T; Tanaka T; Inoue H; Iwahashi M; Kanamono T; Nakano T; Uchimura S; Izumihara T; Yamazaki A; Karyekar CS; Takeuchi T; Mod Rheumatol; 2015 Sep; 25(5):665-71. PubMed ID: 25698370 [TBL] [Abstract][Full Text] [Related]
18. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. Russell AS; Wallenstein GV; Li T; Martin MC; Maclean R; Blaisdell B; Gajria K; Cole JC; Becker JC; Emery P Ann Rheum Dis; 2007 Feb; 66(2):189-94. PubMed ID: 16984942 [TBL] [Abstract][Full Text] [Related]
19. Biologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan. Takeuchi T; Matsubara T; Ohta S; Mukai M; Amano K; Tohma S; Tanaka Y; Yamanaka H; Miyasaka N Rheumatology (Oxford); 2015 Apr; 54(4):683-91. PubMed ID: 25257039 [TBL] [Abstract][Full Text] [Related]
20. Tocilizumab inhibits structural joint damage and improves physical function in patients with rheumatoid arthritis and inadequate responses to methotrexate: LITHE study 2-year results. Fleischmann RM; Halland AM; Brzosko M; Burgos-Vargas R; Mela C; Vernon E; Kremer JM J Rheumatol; 2013 Feb; 40(2):113-26. PubMed ID: 23322466 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]